Loading
A phase 2 trial of Flonoltinib 75mg in myeloproliferative neoplasms, run by Chengdu Zenitar Biomedical Technology Co., Ltd, now recruiting.
Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera is a phase 2 interventional study registered as NCT07232290 by Chengdu Zenitar Biomedical Technology Co., Ltd, with 60 participants planned, started 2025-09-23 and due to reach its primary completion in 2027-07-30. Interventions recorded: Flonoltinib 75mg, Flonoltinib 100mg, Flonoltinib 125mg and Extended Phase Dose Group.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Chengdu Zenitar Biomedical Technology and the tag pipeline.
Shares Chengdu Zenitar Biomedical Technology and the tag pipeline.
Shares Chengdu Zenitar Biomedical Technology and the tag pipeline.
Shares Chengdu Zenitar Biomedical Technology and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Chengdu Zenitar Biomedical Technology and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/